us clinical guidance

Acute sore throat and streptococcal pharyngitis

US risk assessment, selective group A streptococcal testing, antibiotic stewardship and deep-neck-infection safety for children and adults.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Children aged three years or older and adults with acute pharyngeal symptoms. The 2025 IDSA update covers clinical scoring to decide who should be tested; it is Part 1 of a multi-part update, so treatment statements here remain separately attributed to current CDC outpatient guidance. Infants, immunocompromised patients and airway emergencies need tailored care.

The Bottom Line

  • Most acute sore throats are viral. Use a validated clinical scoring system to identify low-probability patients who are unlikely to benefit from group A streptococcal testing rather than testing every presentation.
  • Consider testing despite a low score when risk is unusually high, including household GAS exposure, previous rheumatic fever or signs of scarlet fever, deep-space infection or streptococcal toxic shock.
  • Do not diagnose GAS from symptoms alone when testing is indicated; in adults, treat a confirmed infection and do not prescribe an antibiotic after a negative rapid antigen detection result.
  • Penicillin or amoxicillin remains first-line CDC treatment for confirmed GAS when appropriate; verify allergy phenotype and use local resistance information for non-beta-lactam alternatives.

Practical clinical workflow

1
Assess duration, fever, cough, coryza, conjunctivitis, oral ulcers, rash, tender nodes, tonsillar findings, exposure, vaccination and sexual history when relevant, while checking hydration and airway stability.
2
Apply a chosen score consistently in patients aged three years or older, then combine the result with high-risk features, local epidemiology and patient context to decide whether RADT, NAAT or culture is warranted.
3
Give analgesia, hydration advice and return precautions for viral or test-negative illness; for confirmed GAS, prescribe a source-supported regimen and explain completion, adverse effects and transmission precautions.
4
Reassess worsening, persistent or recurrent illness for peritonsillar or retropharyngeal abscess, epiglottitis, Lemierre syndrome, mononucleosis, acute HIV, gonococcal infection or another non-GAS cause.

Safety boundaries and escalation

  • Drooling, stridor, respiratory distress, tripod positioning, inability to swallow secretions, toxic appearance, trismus, neck swelling or a muffled voice requires urgent airway-capable assessment.
  • The 2025 IDSA score recommendation does not apply to children younger than three years because typical scoring features do not perform reliably in that group.
  • Do not treat a likely GAS carrier who has a viral syndrome merely because an indiscriminate test is positive; align testing with pretest probability to reduce false attribution and antibiotic harm.
  • Report and manage invasive GAS, scarlet-fever clusters or public-health concerns under applicable state and local rules; outpatient pharyngitis guidance is not an invasive-infection protocol.

Localization

US practice uses IDSA 2025 risk assessment and CDC testing/treatment stewardship. IDSA Part 2 was still pending at the source-check date, so this page must be updated when that treatment component is released.

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Infectious Diseases Society of America2025 Clinical Practice Guideline Update on Group A Streptococcal Pharyngitis: Risk Assessment Using Clinical Scoring Systems in Children and AdultsPart 1; literature search through March 2025 路 published 2025-10-14 路 accessed 2026-08-20
    view source
  2. Centers for Disease Control and PreventionOutpatient Clinical Care for Adults: Antibiotic Prescribing and Useupdated 2024-04-16 路 accessed 2026-08-20
    view source
  3. Centers for Disease Control and PreventionOutpatient Clinical Care for Pediatric Populations: Antibiotic Prescribing and Useupdated 2024-04-22 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.